Heparin-Induced Thrombocytopenia (HIT) Clinical Trials

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction where exposure to heparin triggers the formation of IgG antibodies against complexes of platelet factor 4 (PF4) and heparin. These antibodies bind to platelets and activate them, causing both a drop in platelet count (thrombocytopenia) and a paradoxical increase in blood clot formation (thrombosis). This makes HIT uniquely dangerous because the expected response to low platelets would be bleeding, but HIT patients actually clot.

The most common symptoms of Heparin-Induced Thrombocytopenia include Drop in platelet count by 50% or more, typically 5-10 days after starting heparin, New blood clots in veins or arteries despite being on a blood thinner, Skin reactions at heparin injection sites, including redness or tissue death, Deep vein thrombosis or pulmonary embolism, Stroke, heart attack, or limb ischemia from arterial clots, among others. Occurs in approximately 0.5-5% of patients exposed to heparin, depending on the type and duration of heparin used and the clinical setting. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Heparin-Induced Thrombocytopenia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Managing HIT requires switching to alternative anticoagulants quickly, and the current options each have limitations in terms of monitoring requirements, route of administration, or lack of reversal agents. Cadrenal Therapeutics' CAD-1005 (formerly VLX-1005) has received both Orphan Drug and Fast Track designations from the FDA for heparin-induced thrombocytopenia, which reflects the significant unmet need in this space.

Yes. As of October 21, 2026, 2 FDA-approved medicines have a current label that names Heparin-Induced Thrombocytopenia: Argatroban; and Bivalirudin. Corticosteroids and immune globulins count once each.

Heparin-Induced Thrombocytopenia is an acquired condition, not an inherited one. Type II HIT is an antibody reaction against platelet factor 4 bound to heparin, typically 5 to 14 days after exposure; no genetic test has a diagnostic role. Occurs in approximately 0.5-5% of patients exposed to heparin, depending on the type and duration of heparin used and the clinical setting.

Eligibility for Heparin-Induced Thrombocytopenia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Heparin-Induced Thrombocytopenia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.